Liraglutide in the morning or at night?

Liraglutide is injected once daily, Liraglutide can be injected subcutaneously in the morning or at night, as its pharmacological action and pharmacokinetic characteristics make it suitable for injection at any time of the day, only one injection is required per day and the injection is not influenced by diet, so it can be given in the morning or at night.

Diet has little effect on liraglutide because liraglutide is injected subcutaneously and absorbed into the bloodstream where it binds to albumin, creating a slow-release reservoir that slows the release, so you only need to inject it subcutaneously at the same time each day.

Typical onset of action: Subcutaneous injection of 0.6mg reaches maximum hypoglycemic effect after 8-12 hours, with effects lasting up to 13 hours.

Increase or decrease: Liraglutide is a prescription drug and should be used in accordance with the dosage prescribed by the doctor. Increase or decrease in dosage should be based on the blood glucose monitoring level and evaluated by the doctor, and the dosage should be gradually increased or decreased under the doctor's guidance. If you need to stop taking the drug and change to other hypoglycemic drugs after the doctor's evaluation, you need to change the hypoglycemic drug treatment under the doctor's guidance, and remember not to adjust the drug on your own. Otherwise, it may cause adverse medication reactions.

Precautions:

Treatment is accompanied by transient gastrointestinal adverse reactions, including nausea, vomiting and diarrhea. They usually diminish after 2-3 days of administration.

 A few cases of acute pancreatitis have been reported. Patients should be aware of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain. If pancreatitis is suspected, you should discontinue and other potentially suspicious medications and seek prompt medical attention.

 Patients receiving liraglutide in combination with sulfonylureas may be at increased risk of hypoglycemia. Reducing the dose of sulfonylureas may reduce the risk of hypoglycemia.

Contraindications：

Be alert for symptoms of acute pancreatitis such as persistent vomiting and severe abdominal pain. If pancreatitis is suspected, the drug should be discontinued; if pancreatitis is confirmed, it should not be used.

Liraglutide should not be used as an insulin replacement drug and should not be used in type 1 diabetes mellitus and diabetic ketoacidosis.

Acute renal failure and exacerbation of chronic renal failure have been reported with use of the drug; renal function is usually restored by discontinuation of the drug. The risk of renal impairment may be increased by combining other drugs that can affect renal function or by being dehydrated.

Treatment may be accompanied by transient gastrointestinal adverse reactions, including nausea, vomiting, and diarrhea.

Be sure to prevent hypoglycemia if you are driving and operating machinery, especially if liraglutide is combined with a sulfonylurea.

Observe for signs and symptoms of anaphylactic reactions during administration. Antibodies may develop in a small proportion of the population, and the hypoglycemic effect of liraglutide should be closely monitored.

Special Precautions for Use and Other Handling Liraglutide should be used only when colorless and clear. It should not be used after freezing.

The information is from the Internet and is for reference only.